Moderna (MRNA) Competitors

argenx (NASDAQ:ARGX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Which has more risk and volatility, ARGX or MRNA?

argenx has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Which has higher valuation and earnings, ARGX or MRNA?

argenx has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$2.58B	13.62	-$295.05M	$16.21	35.50
Moderna	$3.14B	3.41	-$3.56B	-$8.73	-3.17

Does the media prefer ARGX or MRNA?

In the previous week, Moderna had 12 more articles in the media than argenx. MarketBeat recorded 20 mentions for Moderna and 8 mentions for argenx. argenx's average media sentiment score of 0.80 beat Moderna's score of 0.59 indicating that argenx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenx	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	7 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer ARGX or MRNA?

argenx received 449 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 67.58% of users gave argenx an outperform vote while only 53.07% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
argenx	Outperform Votes 665 67.58%	Underperform Votes 319 32.42%
Moderna	Outperform Votes 216 53.07%	Underperform Votes 191 46.93%

Do insiders and institutionals have more ownership in ARGX or MRNA?

60.3% of argenx shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 2.4% of argenx shares are held by company insiders. Comparatively, 11.0% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is ARGX or MRNA more profitable?

argenx has a net margin of -2.11% compared to Moderna's net margin of -110.04%. argenx's return on equity of -1.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenx	-2.11%	-1.45%	-1.29%
Moderna	-110.04%	-28.74%	-21.83%

Do analysts prefer ARGX or MRNA?

argenx currently has a consensus price target of $709.18, indicating a potential upside of 23.24%. Moderna has a consensus price target of $53.58, indicating a potential upside of 93.57%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.05
Moderna	4 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Summary

argenx beats Moderna on 12 of the 19 factors compared between the two stocks.